A Nordic registry-based study of drug treatment patterns in overactive bladder patients-Reference-Cited by-同舟云学术

A Nordic registry-based study of drug treatment patterns in overactive bladder patients

Published:2019-06-14 Issue:4 Volume:53 Page:246-254
ISSN:2168-1805
Container-title:Scandinavian Journal of Urology
language:en
Short-container-title:Scandinavian Journal of Urology

Author:

Milsom Ian¹,Schiotz Hjalmar A.²,Svensson Maja³,Kilany Suzanne³,Hansson Fredrik⁴

Affiliation:

1. Department of Obstetrics and Gynecology, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden;

2. Department of Obstetrics & Gynecology, Vestfold Hospital Trust, Tønsberg, Norway;

3. Department of Medical Affairs, Astellas Pharma A/S, Kastrup, Denmark;

4. Department of Biometrics, CTC Clinical Trial Consultants AB, Uppsala, Sweden

Funder

Astellas Nordic Baltic Op

Publisher

Informa UK Limited

Subject

Urology,Nephrology

Link

https://www.tandfonline.com/doi/pdf/10.1080/21681805.2019.1619832

Reference26 articles.

1. Persistence with antimuscarinic therapy in patients with overactive bladder

2. Population-Based Survey of Urinary Incontinence, Overactive Bladder, and Other Lower Urinary Tract Symptoms in Five Countries: Results of the EPIC Study

3. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction

4. Nordic Council of Ministers. Nordic Statistics 2016 [accessed 2017 Oct 3]. Available at: http://norden.diva-portal.org/smash/record.jsf?pid=diva2%3A1040725&dswid=-2515.

5. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient and Clinician Challenges with Anticholinergic Step Therapy in the Treatment of Overactive Bladder: A Narrative Review;Advances in Therapy;2023-09-19

2. Treatment of bladder dysfunction with solifenacin: is there a risk of dementia or cognitive impairment?;Brazilian Journal of Medical and Biological Research;2022

3. Mirabegron has longer treatment persistence than antimuscarinics: Real‐world data from a Korean national cohort database;Neurourology and Urodynamics;2021-09-06